Fallopian Tube Cancer

• EMA approval · 2026-02-05
  EMA Authorised: Avzivi (bevacizumab) — FGK Representative Service GmbH

  EMA authorised Avzivi (bevacizumab) for multiple indications including colorectal cancer, non-small cell lung cancer, renal cell carcinoma, …

• EMA approval · 2026-01-28
  EMA Authorised: Abevmy (bevacizumab) — Biosimilar Collaborations Ireland Limited

  EMA authorised Abevmy (bevacizumab) as a biosimilar. It is approved for several cancer indications including colorectal, breast, ovarian, fa…

• EMA approval · 2026-01-28
  EMA Authorised: Oyavas (bevacizumab) — STADA Arzneimittel AG

  EMA authorised Oyavas, a bevacizumab biosimilar by STADA, for multiple indications including colorectal, breast, ovarian, fallopian tube, pe…

• EMA approval · 2026-01-28
  EMA Authorised: Vegzelma (bevacizumab) — Celltrion Healthcare Hungary Kft.

  EMA authorised Vegzelma, a bevacizumab biosimilar from Celltrion Healthcare Hungary Kft., for multiple cancers including colorectal, breast,…

• EMA approval · 2026-01-28
  EMA Authorised: Aybintio (bevacizumab) — Samsung Bioepis NL B.V.

  The EMA authorised Aybintio, a bevacizumab biosimilar from Samsung Bioepis NL B.V., for multiple cancer indications including colorectal, br…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• EMA approval · 2026-01-27
  EMA Authorised: Mvasi (bevacizumab) — Amgen Technology (Ireland) UC

  EMA authorised Mvasi (bevacizumab) from Amgen as a biosimilar to bevacizumab for multiple cancer indications including renal cell carcinoma,…

• EMA approval · 2026-01-27
  EMA Authorised: Avastin (bevacizumab) — Roche Registration GmbH

  The EMA authorised Avastin (bevacizumab) under Roche Registration GmbH for multiple cancer indications. The listed diseases include non-smal…

• EMA approval · 2026-01-23
  EMA Authorised: Elahere (mirvetuximab soravtansine) — AbbVie Deutschland GmbH & Co. KG

  The European Medicines Agency authorised Elahere (mirvetuximab soravtansine) for ovarian cancer, fallopian tube cancer and peritoneal cancer…

• FDA approval · 2024-03-22
  FDA Approved: ELAHERE — Supplemental Application (ImmunoGen, Inc.)

  FDA approves a supplemental application for ELAHERE (mirvetuximab soravtansine) from ImmunoGen, Inc. The approval updates the labeling to re…

• FDA approval · 2023-05-31
  FDA Approved: LYNPARZA — Supplemental Application (AstraZeneca Pharmaceuticals LP)

  The FDA approved a supplemental application for LYNPARZA (olaparib) from AstraZeneca Pharmaceuticals LP, resulting in changes to the product…

• FDA approval · 2023-04-26
  FDA Approved: ZEJULA — Original Application (GlaxoSmithKline LLC)

  FDA approved ZEJULA (niraparib) in an original application submitted by GlaxoSmithKline LLC.

• FDA approval · 2022-11-14
  FDA Approved: ELAHERE — Original Application (ImmunoGen, Inc.)

  The FDA approved ELAHERE (mirvetuximab soravtansine) from ImmunoGen as the original approval for FRα-positive, platinum-resistant epithelial…

• FDA approval · 2022-04-13
  FDA Approved: ALYMSYS — Original Application (Amneal Pharmaceuticals LLC)

  FDA approves ALYMSYS as a biosimilar to bevacizumab (bevaczizumab-maly) from Amneal Pharmaceuticals LLC under an original Biologics License …

• FDA approval · 2021-09-09
  FDA Approved: TALZENNA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

  FDA approved a supplemental application for TALZENNA (talazoparib) submitted by Pfizer Laboratories Div Pfizer Inc.

• FDA approval · 2020-05-15
  FDA Approved: RUBRACA — Supplemental Application (pharmaand GmbH)

  The FDA approved a supplemental application for RUBRACA (rucaparib) submitted by pharmaand GmbH.

• FDA approval · 2019-06-27
  FDA Approved: ZIRABEV — Original Application (Pfizer Laboratories Div Pfizer Inc)

  FDA approves ZIRABEV (bevacizumab-bvzr) from Pfizer as a biosimilar to Avastin under an Original Application. The approval covers multiple b…

• CLINICAL_TRIALS approval · 2017-10-25
  Clinical Trial Update: Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

  Update notes that Olaparib is available via an expanded access program as maintenance therapy for ovarian, fallopian tube, or primary perito…

• FDA approval · 2017-09-14
  FDA Approved: MVASI — Original Application (Amgen, Inc)

  The FDA approved MVASI (bevacizumab-awwb) from Amgen as a biosimilar to Avastin, marking the original application granting U.S. approval for…